lobenzarit 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antiarthritic substances, acting like clobuzarit and lobenzarit 1591 63329-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lobenzarit
prevents autoimmune kidney disease in hybrid mice; RN given refers to parent cpd
  • Molecular weight: 291.69
  • Formula: C14H10ClNO4
  • CLOGP: 5.46
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 86.63
  • ALOGS: -4.36
  • ROTB: 4

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.307 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 10.162 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 32.285 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 4.624 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 0.590 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 0.630 % Moderate 0.73
herg hERG pIC50 3.806 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 15.346 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 2.754 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 0.190 % Moderate 0.73
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 57
kinase-selectivity-class ACVR2A,ACVR2B,ALK,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,GSK3A,GSK3B,JAK1,JAK2,MAP2K3,MAP2K6,MAP3K21,MAP4K1,MAP4K3,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MTOR,PIK3CG,PRKDC,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ULK2 42
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 8.204 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 19.498 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 1.900 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.632 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.660 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 31.405 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 69.220 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 0.220 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 997.700 uM Moderate 0.73

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.95 acidic
pKa2 4.56 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C0065141 UMLSCUI
CHEBI:135215 CHEBI
CHEMBL1986706 ChEMBL_ID
C015735 MESH_SUPPLEMENTAL_RECORD_UI
3946 PUBCHEM_CID
5106 INN_ID
915EE91P39 UNII
915EE91P39 INXIGHT DRUGS

Pharmaceutical products:

None